Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis).
about
Cardiovascular risk in dialysis patients: a comparison of risk factors and cardioprotective therapy between 1996 and 2001Calciphylaxis--a topical overviewEfficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patientsDrug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects.Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patientsThe roles of the skeleton and phosphorus in the CKD mineral bone disorderEndothelin but Not Angiotensin II May Mediate Hypertension-Induced Coronary Vascular Calcification in Chronic Kidney DiseaseChronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease.Bone Parameters and Risk of Hip and Femur Fractures in Patients on Hemodialysis.Vitamin K-dependent proteins, warfarin, and vascular calcificationPreclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries.Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?14. Recent Approaches to Therapy: Is There Real Progress?One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor.Deleterious effects of phosphate on vascular and endothelial function via disruption to the nitric oxide pathway.Ischemic myopathy revealing systemic calciphylaxis.Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.Digital gangrene and pneumatosis intestinalis associated with calciphylaxis.
P2860
Q28167686-4BBE20E9-82F6-4134-B629-8AB80BAB3B19Q28239109-49ABB401-220C-47B7-808C-167771E01F56Q33432308-72FADDB8-2F0B-4BC6-977E-68E1B96E313DQ34116591-244FB873-2933-4B2C-BC0D-BFFE34AED538Q34413591-D9AC635C-70F1-4C47-A0C6-ED01AE9AD4E9Q34463433-A1056DF5-0A22-492E-91B5-CC3F482445F7Q35013304-F72858C1-8A61-48A4-89D4-6F4097666B47Q35072941-73E27F1F-D989-4B2A-95BB-A55AB95C5E16Q35249551-EF2A8698-1E1F-4D8F-912B-206FBD562222Q36965098-5347820D-B33A-43A9-8B54-DAD19774EC4FQ37170124-C3CCF86F-13BD-43A1-9215-FC88B69B4A29Q37204047-EF2E9183-72B6-45E2-A343-F84BBFFA12B4Q37276028-968450D3-D2F7-4C8B-8766-AB2D3E8C0075Q39440902-594A06E1-AC51-47C0-B73E-94C768569246Q41809621-965B28E3-8CE8-41CE-A489-B6D2450F55E6Q46034498-87C28C76-E1B6-4856-9645-DF9A96AD6187Q46612804-9265CCAD-B710-4FF6-9E8C-A381EA0E96F8Q52673652-F6B64A41-6178-4422-875C-73C756C76F55Q52946157-1AE871FE-2C31-4663-B041-CCE2D39E0888Q55347421-01119F59-161E-447F-89D2-E198925E3FEBQ55383946-249C073D-B442-4136-BFE0-A4CAF126AC67
P2860
Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis).
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Control of serum phosphorus: i ...... rteriolopathy (calciphylaxis).
@ast
Control of serum phosphorus: i ...... rteriolopathy (calciphylaxis).
@en
Control of serum phosphorus: i ...... calcific uremic arteriolopathy
@nl
type
label
Control of serum phosphorus: i ...... rteriolopathy (calciphylaxis).
@ast
Control of serum phosphorus: i ...... rteriolopathy (calciphylaxis).
@en
Control of serum phosphorus: i ...... calcific uremic arteriolopathy
@nl
prefLabel
Control of serum phosphorus: i ...... rteriolopathy (calciphylaxis).
@ast
Control of serum phosphorus: i ...... rteriolopathy (calciphylaxis).
@en
Control of serum phosphorus: i ...... calcific uremic arteriolopathy
@nl
P1476
Control of serum phosphorus: i ...... rteriolopathy (calciphylaxis).
@en
P2093
P304
P356
10.1097/00041552-200111000-00003
P577
2001-11-01T00:00:00Z